Genentech and its corporate parent Roche Group were slapped with a product liability class action Wednesday in California Northern District Court accusing the companies of failing to warn the U.S. military and service members about neuropsychiatric risks associated with the antimalarial drug Mefloquine. The complaint, filed by Kozyak Tropin & Throckmorton and Moore & Lee, seeks medical monitoring for military members who took Mefloquine and experienced experienced side effects including pain, sleep disturbances, skin disorders, fatigue and cognitive decline. Counsel have not yet appeared for the defendants. The case is 3:23-cv-00928, Caston et al v. F. Hoffmann-La Roche, Inc. et al.

This suit was surfaced by Radar, a source for high-speed legal news and litigation updates personalized to your practice. Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.